Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
复制标题
DOI:
10.1007/s11899-018-0463-9
复制
发表时间:
2018-08
影响因子:
2.9
通讯作者:
Brent Ferrell P Jr
中科院分区:
文献类型:
--
作者:
Ivy KS;Brent Ferrell P Jr
Immune dysregulation is a defining feature of myelodysplastic syndromes (MDS). Recently, several studies have further defined the complex role of immune alterations within MDS. Herein we will summarize some of these findings and discuss the therapeutic strategies currently in development. Immune alterations in MDS are complex, heterogeneous and intertwined with clonal hematopoiesis and stromal cell dysfunction. Inflammation in MDS proceeds as a vicious cycle, mediated in large part by secreted factors, which induce cell death and activate innate immune signaling. Therapeutic targeting of this variable immune dysregulation has led to modest responses thus far, but incorporation of the growing repertoire of immunotherapy brings new potential for improved outcomes. The immune milieu is variable across the spectrum of MDS subtypes, with a changing balance of inflammatory and suppressive cellular forces from low to high risk disease.
登录
查看更多内容
影响因子:
12.8
作者:
Brayer J;Lancet JE;Powers J;List A;Balducci L;Komrokji R;Pinilla-Ibarz J
通讯作者:
Pinilla-Ibarz J
影响因子:
11.4
作者:
Bouscary, D;DeVos, J;FontenayRoupie, M
通讯作者:
FontenayRoupie, M
影响因子:
2.6
作者:
Boddu P;Kantarjian H;Garcia-Manero G;Allison J;Sharma P;Daver N
通讯作者:
Daver N
影响因子:
8.8
作者:
Carey A;Edwards DK 5th;Eide CA;Newell L;Traer E;Medeiros BC;Pollyea DA;Deininger MW;Collins RH;Tyner JW;Druker BJ;Bagby GC;McWeeney SK;Agarwal A
通讯作者:
Agarwal A
影响因子:
11.4
作者:
Eksioglu EA;Chen X;Heider KH;Rueter B;McGraw KL;Basiorka AA;Wei M;Burnette A;Cheng P;Lancet J;Komrokji R;Djeu J;List A;Wei S
通讯作者:
Wei S